



Part D Drug Appeals – Independent Review Entity Change

Effective February 1, 2021, C2C Innovative Solutions Inc. will be responsible for conducting:

- Reconsiderations of adverse Part D coverage determinations and redeterminations
- Adverse redeterminations related to an at-risk determination under a drug management program (DMP)
- Conducting reconsiderations of adverse determinations related to the assessment of a Late Enrollment Penalty (LEP) under the Medicare Part D Program.

Please note this change applies only to Part D. This information is included with member and provider appeal denial letters for HAP Empowered MI Health Link members and Medicare Advantage members with Medicare part D (MAPD) prescription coverage.

Part D Prescription Drug Benefit and DMP At-Risk Appeals
C2C Innovative Solutions, Inc.
Part D Drug Reconsiderations
P.O. Box 44166
Jacksonville, FL 32231-4166